Niel C. Hoglen, Dean M. Anselmo, Masamichi Katori, Marian Kaldas, Xiu‐Da Shen, Karen L. Valentino, Charles Lassman, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski, Douglas G. Farmer – 22 February 2007 – This study examined the efficacy of the caspase inhibitor, IDN‐6556, in a rat model of liver ischemia‐reperfusion injury. Livers from male Sprague‐Dawley rats were reperfused for 120 minutes after 24 hours of 4°C cold storage in University of Wisconsin solution.

Michael Green, Steven A. Webber – 22 February 2007

22 February 2007

Jérémie Gras, Grégoire Wieërs, Jean‐Luc Vaerman, Dinh Quang Truong, Etienne Sokal, Jean‐Bernard Otte, Béatrice Délépaut, Anne Cornet, Jean de Ville de Goyet, Dominique Latinne, Raymond Reding – 22 February 2007 – Cytokine deviation may be a factor contributing to graft acceptance. We analyze, in the context of liver transplantation, circulating cytokine levels and their mRNA precursors in liver biopsy samples to study a putative correlation with early immunologic outcome.

Nicholas Onaca, Gary L. Davis, Robert M. Goldstein, Linda W. Jennings, Göran B. Klintmalm – 22 February 2007 – Hepatocellular carcinoma (HCC) is a common indication for liver transplantation (LT). Currently, deceased donor LT is approved by the United Network for Organ Sharing for patients with HCC who meet the Milan criteria of a single tumor up to 5 cm or up to 3 tumors up to 3 cm as determined by imaging studies. We analyzed data in the International Registry of Hepatic Tumors in Liver Transplantation from 1,206 patients with HCC.

Gerd Otto – 22 February 2007

Johannes Hadem, Volker Westerkamp, Christian Trautwein, Michael Winkler, Michael P. Manns, Carsten Hafer – 22 February 2007

Markus Selzner, Nazia Selzner, Wolfram Jochum, Rolf Graf, Pierre‐Alain Clavien – 22 February 2007 – Although livers exhibit only minimal morphologic changes with age, how older livers tolerate pathologic conditions such as normothermic ischemia is unknown. Young 6‐week‐old mice and old 60‐week‐old mice underwent 60 minutes of hepatic ischemia and various periods of reperfusion. Markers of hepatocyte injury, hepatic energy content, and mitochondrial function were determined.

Tanja Bauer, Matthias Günther, Ulrich Bienzle, Ruth Neuhaus, Wolfgang Jilg – 22 February 2007 – After liver transplantation for hepatitis‐B‐related diseases, patients currently receive lifelong treatment with hepatitis B immunoglobulin to prevent endogenous reinfection with hepatitis B virus (HBV). Active immunization with hepatitis B vaccine would be a preferable alternative; however, most attempts to immunize these patients with standard vaccine have failed.

Jens Rosenau, Nazanin Hooman, Johannes Hadem, Kinan Rifai, Matthias J. Bahr, Gunnar Philipp, Hans L. Tillmann, Juergen Klempnauer, Christian P. Strassburg, Michael P. Manns – 22 February 2007 – Hepatitis B vaccination after liver transplantation for hepatitis B–related liver disease has been investigated as an alternative strategy to reinfection prophylaxis with hepatitis B immunoglobulin (HBIG) with conflicting results. In most studies, HBIG treatment was discontinued before vaccination.